Tiziana Life Sciences (TLSA) announced that dosing has commenced at the fourth clinical site in its ongoing Phase 2 trial evaluating intranasal foralumab in patients with non-active secondary progressive multiple sclerosi, na-SPMS. The University of Massachusetts, UMass, has now joined Brigham and Women’s Hospital, Yale Multiple Sclerosis Center, and Johns Hopkins University Autoimmunity Center of Excellence in actively dosing participants.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Expands Phase 2 Trial for Multiple Sclerosis Treatment
- Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab
- Tiziana Life Sciences files $250M mixed securities shelf
- Tiziana Life Sciences announces dosing of new patients at Yale MS Center
- Tiziana Life Sciences CEO to Present at ROTH Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue